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To the Editor:  Neisseria men-
ingitidis is the etiologic agent of out-
breaks, epidemics, and sporadic cases 
of meningitis or meningococcemia. 
Such infections have high illness and 
death rates, especially in children <5 
years of age and adolescents. N. men-
ingitidis serogroups A, B, C, Y, and 
W135 cause most meningococcal dis-
ease worldwide (1).
In Colombia, public health no-
tiﬁ  cation is required for all cases of 
invasive meningococcal disease. This 
reporting system is supported by a 
laboratory-based surveillance network 
for acute bacterial meningitis that has 
been coordinated by the Microbiol-
ogy Group at the Instituto Nacional de 
Salud since 1994 (2,3). Clinical labo-
ratories in Colombia submit isolates 
with associated information including 
geographic origin, specimen source, 
age, sex, and clinical diagnosis of the 
patient. Identiﬁ  cation is conﬁ  rmed by 
traditional phenotypic methods (4). 
Isolates are serogrouped by agglutina-
tion using commercial antisera (Difco, 
Detroit, MI, USA, and Becton Dick-
inson, Franklin Lakes, NJ, USA) and 
subtyped by dot blot with monoclo-
nal antibodies (RIVM, Bilthoven, the 
Netherlands; and Institute Adolfo Lutz 
[IAL], São Paulo, Brazil) (5). Antimi-
crobial drug susceptibility testing for 
penicillin and rifampin is performed 
by the agar dilution, according to Clin-
ical and Laboratory Standards Institute 
methods (6); for the breakpoints, we 
used those recommended by the Mesa 
Española de Normalización de la Sen-
sibilidad y Resistencia a los Antimi-
crobianos (MENSURA) group (7). 
The reference laboratory participates 
in an external quality assurance pro-
gram coordinated by the Pan Ameri-
can Health Organization (Sistema 
Regional de Vacunas [SIREVA] II, 
PAHO, Washington, DC, USA) with 
the Carlos III Institute, Madrid, Spain, 
and the IAL.
From 1994 through 2006, 434 N. 
meningitidis isolates were received by 
the Microbiology Group, from 22 of 
35 departments (political divisions) 
and the Capital District: 119 (27.4%) 
from Antioquia, 117 (27.0%) from 
Bogotá, DC, 72 (16.6%) from Valle, 
25 (5.8%) from Risaralda, 21 (4.8%) 
from Caldas, and 80 (18.4%) from 18 
other departments. Distribution by de-
partment is published at the Institute’s 
website (www.ins.gov.co) (8). Accord-
ing to public health reports, the refer-
ence laboratory is receiving ≈27% of 
the clinical case isolates. A slight 
majority (53.8%) were cultured from 
male patients. The age of patients was 
available for 396 isolates: 254 (64.1%) 
were <1–9 years of age, 71 (17.9%) 
10–19 years, 41 (10.4%) 20–39 years, 
21 (5.3%) 40–59 years, and 9 (2.3%) 
>59 years. Three hundred ninety-two 
isolates (90.3%) were recovered from 
cerebrospinal  ﬂ   uid and 42 (9.7%) 
from blood cultures. The diagnosis for 
420 (96.8%) patients was meningitis; 
11 (2.5%) patients had sepsis or bacte-
remia, and 3 (0.7%) had other invasive 
diseases (pneumonia, encephalopathy, 
or cellulitis).
Serogroup distribution was 338 
(77.9%) group B, 42 (9.7%) group C, 
40 (9.2%) group Y, and 2 (0.5%) group 
W135; 12 isolates were nongroupable. 
There was little annual variation for 
groups B and C, but there was an un-
expected increase in serogroup Y (Fig-
ure), from 0% in 1994 to 50% in 2006. 
When the period 1994–2002 was com-
pared with 2003–2006, this change 
was signiﬁ  cant, increasing from 2.2% 
to 29.5% (p<0.001).
Antimicrobial drug–susceptibil-
ity testing showed that 17% of the 
isolates had intermediate resistance 
to penicillin (MIC 0.125–1.0 μg/mL) 
and 0.5% high resistance (>2.0 μg/
mL); only 1 isolate was resistant to 
rifampin (>4.0 μg/mL). Penicillin re-
sistance was not associated with any 
speciﬁ  c serogroup.
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From the 40 serogroup Y isolates, 
22 (55%) were from Bogotá, DC, 5 
(12.5%) from Antioquia, 5 (12.5%) 
from Valle, and the remaining 8 (20%) 
from 5 other departments. Age distri-
bution of patients who provided the 
isolates was as follows: 15 (37.5%) 
were <1–9 years of age, 7 (17.5%) 
10–19 years, 11 (27.5%) 20–39 years, 
4 (10%) 40–59 years, and 3 (7.5%) 
>59 years.
Subtyping of the 40 Y isolates 
showed that 30 (75.0%) were serotype 
14 with 3 different subtypes: 23 were 
Y:14:NST; 6 were Y:14:P1.5,2; and 
1 was, Y:14:P1.10. Four (9.8%) were 
nontypeable (NT) with 2 subtypes: 3 
were NT:P1.5,2, and 1 was NT:NST; 
the remaining 6 (14.6%) belonged to 
5 other serotypes. Intermediate resis-
tance to penicillin was found in 5% of 
the serogroup Y isolates, and one was 
resistant to rifampin.
From 1994 through 2005, the lab-
oratory-based surveillance program 
identiﬁ  ed serogroup B as the most fre-
quently isolated serogroup that caused 
acute bacterial meningitis in Colom-
bia. In 2003, there was an unexpected 
increase in serogroup Y (Figure), and 
by 2006 it was the most common sero-
group in Colombia. Seventy-ﬁ  ve per-
cent of the isolates collected during 
2002–2006 were recovered from male 
patients younger than 14 years.
An increase in serogroup Y has 
also been reported in Chicago, Illi-
nois, where one third of meningococ-
cal disease cases are caused by this 
serogroup (9). A similar increase has 
been reported in Canada (10). Both the 
United States and Canada have inves-
tigated genetic similarity, and circulat-
ing clonal types have been determined 
(9,10). Similar molecular studies with 
Colombian isolates are under way in 
collaboration with the Carlos III In-
stitute from Spain under PAHO co-
ordination. Our data demonstrate the 
importance of laboratory-based sur-
veillance programs supported by ac-
tive participation of clinical and public 
health laboratories. 
Clara Inés Agudelo,* Olga 
Marina Sanabria,* and María 
Victoria Ovalle*
*Instituto Nacional de Salud, Bogotá, Co-
lombia
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Figure.  Neisseria meningitidis, serogroup distribution by surveillance year, N = 434. 
*p<0.001. 